These data are consistent with the data of a retrospective study recently published by Kobe et al.[26], [35] At the present time, anticancer therapy is currently monitored in the context of hormone-sensitive cancers by regular assay of tumor markers (such as prostate-specific antigen in prostate cancer). This evidence concerns the gene KLK3 and Familial prostate cancer.